{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:52:37Z","timestamp":1771480357050,"version":"3.50.1"},"reference-count":11,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This was a 24-week, multicenter phase- 2 study designed to assess safety, tolerability, and pharmacodynamics of FBS0701, a novel oral chelator, in adults with transfusional iron overload. Fifty-one patients, stratified by transfusional iron intake, were randomized to FBS0701 at either 14.5 or 29 mg\/kg\/d (16 and 32 mg\/kg\/d salt form). FBS0701 was generally well tolerated at both doses. Forty-nine patients (96%) completed the study. There were no drug-related serious adverse events. No adverse events (AEs) showed dose-dependency in frequency or severity. Treatment-related nausea, vomiting, abdominal pain, and diarrhea were each noted in &lt; 5% of patients. Mean serum creatinine did not change significantly from Baseline or between dose groups. Transaminases wer increased in 8 (16%), three of whom acquired HCV on-study from a single blood bank while five had an abnormal baseline ALT. The 24 week mean change in liver iron concentration (\u0394LIC) at 14.5 mg\/kg\/d was +3.1 mg\/g (dw); 29% achieved a decrease in LIC. Mean \u0394LIC at 29 mg\/kg\/d was \u22120.3 mg\/g (dw); 44% achieved a decrease in LIC (P &lt; .03 for \u0394LIC between doses). The safety and tolerability profile at therapeutic doses compare favorably to other oral chelators. This trial was registered at www.clinicaltrials.gov as NCT01186419.<\/jats:p>","DOI":"10.1182\/blood-2011-10-386268","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T06:09:52Z","timestamp":1326866992000},"page":"3263-3268","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload"],"prefix":"10.1182","volume":"119","author":[{"given":"Ellis J.","family":"Neufeld","sequence":"first","affiliation":[{"name":"Children's Hospital, Harvard University, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Galanello","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Cagliari, Cagliari, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[{"name":"Siriraj Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesim","family":"Aydinok","sequence":"additional","affiliation":[{"name":"Pediatric Haematology, Ege University Hospital, Izmir, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[{"name":"Scienze Cliniche e Biologiche, Torino, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[{"name":"Gastroenterology, Children's Hospital & Research Center Oakland, Oakland, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[{"name":"Centro della Microcitemia e delle Anemia Congenite-Ematologia, Ospedale Galliera, Genoa, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrukh T.","family":"Shah","sequence":"additional","affiliation":[{"name":"Haematology, The Whittington Hospital, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[{"name":"Children's Hospital, Harvard University, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Porter","sequence":"additional","affiliation":[{"name":"University College London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Wood","sequence":"additional","affiliation":[{"name":"Cardiology, Children's Hospital Los Angeles, Los Angeles, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Peppe","sequence":"additional","affiliation":[{"name":"FerroKin BioSciences Inc, San Carlos, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Jones","sequence":"additional","affiliation":[{"name":"FerroKin BioSciences Inc, San Carlos, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Hugh Young","family":"Rienhoff","sequence":"additional","affiliation":[{"name":"FerroKin BioSciences Inc, San Carlos, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"9","key":"2019111808141463300_B1","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","article-title":"Oral chelators, deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.","volume":"107","author":"Neufeld","year":"2006","journal-title":"Blood"},{"key":"2019111808141463300_B2","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/hlca.19800630608","article-title":"Stoffwechselprodukte von mikroorganismen (193 Mitteilung): ferrithiocin.","volume":"63","author":"Naegeli","year":"1980","journal-title":"Helv Chim Acta"},{"issue":"5","key":"2019111808141463300_B3","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1021\/ja00161a032","article-title":"Coordination chemistry of microbial iron transport: 42. Structural and spectroscopic characterization of diastereomeric chromium(III) and cobalt(III) complexes of desferrithiocin.","volume":"112","author":"Hahn","year":"1990","journal-title":"J Am Chem Soc"},{"issue":"13","key":"2019111808141463300_B4","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1021\/jm800154m","article-title":"Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.","volume":"51","author":"Bergeron","year":"2008","journal-title":"J Med Chem"},{"key":"2019111808141463300_B5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3324\/haematol.2010.034405","article-title":"A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.","volume":"96","author":"Rienhoff","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"2019111808141463300_B6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2007-08-109306","article-title":"Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.","volume":"111","author":"Cohen","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111808141463300_B7","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"issue":"14","key":"2019111808141463300_B8","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1182\/blood-2010-01-261289","article-title":"Iron chelating therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.","volume":"116","author":"Lee","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111808141463300_B9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","article-title":"Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-year prospective study.","volume":"80","author":"Porter","year":"2008","journal-title":"Eur J Haematol"},{"key":"2019111808141463300_B10","first-page":"696","article-title":"Effects of deferasirox on renal hemodynamics in patients with beta-thalassemia: first interim analysis.","volume":"95","author":"Piga","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"2019111808141463300_B11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/MPH.0b013e3181ec0c4d","article-title":"Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.","volume":"32","author":"Baum","year":"2010","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/14\/3263\/1351287\/zh801412003263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/14\/3263\/1351287\/zh801412003263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T23:18:25Z","timestamp":1713395905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/14\/3263\/29572\/A-phase-2-study-of-the-safety-tolerability-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,5]]},"references-count":11,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,4,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-10-386268","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,5]]}}}